Treatment of Myeloproliferative Neoplasms with Janus Kinase Inhibitors: A Meta-Analysis of Cardiovascular Safety

被引：0
|
作者：
Long, Edouard [1 ]
Dunn, Roberta [1 ]
Li Gagnon, Laura [2 ]
Harrison, Claire [2 ]
Yang, Yunfan [2 ,3 ]
O'Sullivan, Jennifer [4 ]
机构：
[1] Kings Coll London, GKT Sch Med Educ, London, England
[2] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England
[3] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China
[4] Guys & St ThomasNHS Fdn Trust, Dept Clin Haematol, London, England
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-202359
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3168 / 3169
页数：2
相关论文
共 50 条
  • [41] Comparative Efficacy of Janus Kinase Inhibitors and TNF Inhibitors in Ankylosing Spondylitis: A Network Meta-Analysis
    Castro, Adela
    Diaz, Jesus
    Quiceno, Guillermo
    Cush, John
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [42] Efficacy and safety of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: a meta-analysis
    Xie, Bingqian
    Gao, Minjie
    Hu, Liangning
    Kong, Yuanyuan
    Gao, Lu
    Wang, Houcai
    Yang, Guang
    Zhang, Yiwen
    Tao, Yi
    Xu, Hongwei
    Zhan, Fenghuang
    Wu, Xiaosong
    Shi, Jumei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (02): : 1815 - 1821
  • [43] Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
    Wan, Ziqi
    Han, Bing
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [44] Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)
    Pemmaraju, Naveen
    Mesa, Ruben
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 649 - 651
  • [45] Comparative Efficacy and Safety of Janus Kinase Inhibitors and Secukinumab in Patients with Active Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
    Lee, Young Ho
    PHARMACOLOGY, 2022, 107 (11-12) : 537 - 544
  • [46] Comparison of the Efficacy and Safety of Janus Kinase Inhibitors and DMARDs in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis
    Castro, Adela
    Diaz, Jesus
    Quiceno, Guillermo
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [47] COMPARATIVE EFFICACY OF JANUS KINASE INHIBITORS VERSUS USTEKINUMAB IN ULCERATIVE COLITIS TREATMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Albandak, Maram
    Abbarh, Shahem
    Sawaf, Bisher
    Hallak, Yusuf O.
    Abu-Rumaileh, Mohammed
    Rabeeah, Sana
    Akhras, Aya
    Alhayek, Mohammad
    Dahhan, Wael
    Alastal, Yaseen
    INFLAMMATORY BOWEL DISEASES, 2025, 31 : S8 - S8
  • [48] Efficacy of Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis: A Meta-analysis and Systematic Review
    Zhang, Tony
    Timmerman, Nicholas
    Lau, Arthur
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) : 991 - 991
  • [49] Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis
    Sureau, Lea
    Orvain, Corentin
    Ianotto, Jean-Christophe
    Ugo, Valerie
    Kiladjian, Jean-Jacques
    Paz, Damien Luque
    Riou, Jeremie
    BLOOD CANCER JOURNAL, 2021, 11 (07)
  • [50] Venous and arterial thromboembolic risk of Janus kinase inhibitors: a systematic review with meta-analysis
    Campanaro, Francesco
    Zaffaroni, Andrea
    Cacioppo, Elettra
    Cappelli, Antonella
    Bertu, Lorenza
    Donadini, Marco Paolo
    Squizzato, Alessandro
    Batticciotto, Alberto
    RHEUMATOLOGY, 2023, 62 (10) : 3245 - 3255
12345